Literature DB >> 16942014

Homobivalent quinazolinimines as novel nanomolar inhibitors of cholinesterases with dirigible selectivity toward butyrylcholinesterase.

Michael Decker1.   

Abstract

Homobivalent dimers of quinazolinimines, which bridge the imine nitrogen atoms via a hepta- and an octamethylene spacer, with different ring sizes of the alicycles were synthesized from the corresponding quinazolinethiones. The resulting compounds show >100-fold increase of inhibitory activities compared to related monomeric compounds yielding low-nanomolar inhibitors. For heptamethylene dimers, mixed inhibition profiles were obtained, whereas for the octamethylene compounds selectivity toward butyrylcholinesterase (>180) can be achieved with an eight-membered alicycle.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16942014     DOI: 10.1021/jm060682m

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  11 in total

1.  Pharmacological properties of bivalent ligands containing butorphan linked to nalbuphine, naltrexone, and naloxone at mu, delta, and kappa opioid receptors.

Authors:  Xuemei Peng; Brian I Knapp; Jean M Bidlack; John L Neumeyer
Journal:  J Med Chem       Date:  2007-04-04       Impact factor: 7.446

2.  Elaborate ligand-based modeling coupled with QSAR analysis and in silico screening reveal new potent acetylcholinesterase inhibitors.

Authors:  Sawsan Abuhamdah; Maha Habash; Mutasem O Taha
Journal:  J Comput Aided Mol Des       Date:  2013-12-12       Impact factor: 3.686

3.  Neuroprotective Tri- and Tetracyclic BChE Inhibitors Releasing Reversible Inhibitors upon Carbamate Transfer.

Authors:  Fouad H Darras; Beata Kling; Jörg Heilmann; Michael Decker
Journal:  ACS Med Chem Lett       Date:  2012-08-22       Impact factor: 4.345

4.  In vivo investigations on the cholinesterase-inhibiting effects of tricyclic quinazolinimines: scopolamine-induced cognitive impairments in rats are attenuated at low dosage and reinforced at higher dosage.

Authors:  D Appenroth; M Decker; C Tränkle; K Mohr; J Lehmann; C Fleck
Journal:  Pflugers Arch       Date:  2007-08-24       Impact factor: 3.657

5.  Modeling in vitro inhibition of butyrylcholinesterase using molecular docking, multi-linear regression and artificial neural network approaches.

Authors:  Fang Zheng; Max Zhan; Xiaoqin Huang; Mohamed Diwan M Abdul Hameed; Chang-Guo Zhan
Journal:  Bioorg Med Chem       Date:  2013-11-08       Impact factor: 3.641

6.  Novel 16-substituted bifunctional derivatives of huperzine B: multifunctional cholinesterase inhibitors.

Authors:  Yu-fang Shi; Hai-yan Zhang; Wei Wang; Yan Fu; Yu Xia; Xi-can Tang; Dong-lu Bai; Xu-chang He
Journal:  Acta Pharmacol Sin       Date:  2009-07-06       Impact factor: 6.150

7.  Development of an in-vivo active reversible butyrylcholinesterase inhibitor.

Authors:  Urban Košak; Boris Brus; Damijan Knez; Roman Šink; Simon Žakelj; Jurij Trontelj; Anja Pišlar; Jasna Šlenc; Martina Gobec; Marko Živin; Larisa Tratnjek; Martina Perše; Kinga Sałat; Adrian Podkowa; Barbara Filipek; Florian Nachon; Xavier Brazzolotto; Anna Więckowska; Barbara Malawska; Jure Stojan; Irena Mlinarič Raščan; Janko Kos; Nicolas Coquelle; Jacques-Philippe Colletier; Stanislav Gobec
Journal:  Sci Rep       Date:  2016-12-21       Impact factor: 4.379

8.  Bivalent Inhibitor with Selectivity for Trimeric MMP-9 Amplifies Neutrophil Chemotaxis and Enables Functional Studies on MMP-9 Proteoforms.

Authors:  Elisa Nuti; Armando Rossello; Doretta Cuffaro; Caterina Camodeca; Jens Van Bael; Dries van der Maat; Erik Martens; Pierre Fiten; Rafaela Vaz Sousa Pereira; Estefania Ugarte-Berzal; Mieke Gouwy; Ghislain Opdenakker; Jennifer Vandooren
Journal:  Cells       Date:  2020-07-07       Impact factor: 6.600

Review 9.  Merged Tacrine-Based, Multitarget-Directed Acetylcholinesterase Inhibitors 2015-Present: Synthesis and Biological Activity.

Authors:  Todd J Eckroat; Danielle L Manross; Seth C Cowan
Journal:  Int J Mol Sci       Date:  2020-08-19       Impact factor: 5.923

10.  Synthesis and biological assessment of KojoTacrines as new agents for Alzheimer's disease therapy.

Authors:  Youssef Dgachi; Hélène Martin; Rim Malek; Daniel Jun; Jana Janockova; Vendula Sepsova; Ondrej Soukup; Isabel Iriepa; Ignacio Moraleda; Emna Maalej; M Carmo Carreiras; Bernard Refouvelet; Fakher Chabchoub; José Marco-Contelles; Lhassane Ismaili
Journal:  J Enzyme Inhib Med Chem       Date:  2019-12       Impact factor: 5.051

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.